The Clinical Trial Engagement Network
The Clinical Trial Engagement Network will serve as the healthcare industry resource addressing a critical need in drug research – improving the representation of diverse populations, including African Americans, Asian Americans and Hispanics, in clinical trials. Clinical trial sponsors that join the Clinical Trial Engagement Network, gain exposure to, and connect with, clinical trial investigators and diverse patients […]
More African Americans need to participate in clinical trials
Washington Post.: February 21, 2014 David Satcher is honorary chairman of the African American Network Against Alzheimer’s and a former surgeon general of the United States. Every February our society measures its progress in the march toward equality as part of Black History Month. But seldom do we discuss inequality in health, an injustice that continues to […]
The Underlying Condition: Increasing Diversity in Clinical Trials
National Journal: February 20, 2014 John J. Castellani is president and CEO of the Pharmaceutical Research and Manufacturers of America, which represents the country’s leading biopharmaceutical research and biotechnology companies. (Courtesy photo) Opinion: African-Americans, at 12 percent of the population, comprise only 5 percent of clinical-trial participants; the numbers for Hispanics are 16 percent and 1 […]
Approaches and Costs for Sharing Clinical Research Data
JAMA: 2/20/14 The generation, dissemination, and sharing of research data are key ingredients in contributing to scientific progress and the public good. Data sharing has been encouraged to facilitate open science within the clinical research enterprise, improve the development of drugs and devices, and benefit public health.1 But sharing data is complex. Investigators generally tend to guard […]
Informed Consent, Comparative Effectiveness, and Learning Health Care
NEJM: 2/20/14 The authors argue that in a learning health care system with ethically robust oversight policies, a streamlined consent process could replace formal written informed-consent procedures for many studies, and patient consent would not be required at all for some trials. Read more
Attitudes toward clinical trials among patients with sickle cell disease
Clin Trials: February 13, 2014 Background A substantial number of planned clinical trials for sickle cell disease (SCD) have terminated early due to insufficient patient enrollment. Purpose To describe attitudes toward clinical trials among a sample of adults with SCD and identify patient-level factors associated with these attitudes. Methods Our data came from a sample (N = 291) of […]
PhRMA Joins Accelerating Medicines Partnership to Advance Discovery and Development of New Treatments
Phrma: 02.04.14 A groundbreaking new partnership was announced earlier today by the National Institutes of Health (NIH). The Accelerating Medicines Partnership (AMP), an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA, aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease. In […]
